Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a market perform rating to an outperform rating in a research report sent to investors on Thursday morning, Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. SVB Leerink upgraded Tandem Diabetes Care from a market perform rating to an outperform rating and lifted their target price for the company from $34.00 to $45.00 in a research report on Thursday. StockNews.com upgraded Tandem Diabetes Care from a sell rating to a hold rating in a report on Friday, April 19th. Stifel Nicolaus boosted their price objective on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a buy rating in a report on Tuesday. Finally, Citigroup boosted their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $39.45.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $35.56 on Thursday. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $40.74. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. The company has a market capitalization of $2.30 billion, a P/E ratio of -10.34 and a beta of 1.12. The stock’s fifty day moving average is $30.74 and its two-hundred day moving average is $25.26.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The business had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Equities analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Investors Weigh In On Tandem Diabetes Care

Several large investors have recently bought and sold shares of the stock. Eminence Capital LP boosted its position in shares of Tandem Diabetes Care by 76.1% during the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock worth $114,028,000 after acquiring an additional 2,372,458 shares in the last quarter. GW&K Investment Management LLC acquired a new position in shares of Tandem Diabetes Care during the 4th quarter worth about $36,288,000. Jennison Associates LLC boosted its position in shares of Tandem Diabetes Care by 252.6% during the 3rd quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company’s stock worth $23,323,000 after acquiring an additional 804,488 shares in the last quarter. Chicago Capital LLC boosted its position in shares of Tandem Diabetes Care by 699.8% during the 3rd quarter. Chicago Capital LLC now owns 904,410 shares of the medical device company’s stock worth $18,785,000 after acquiring an additional 791,336 shares in the last quarter. Finally, Paradice Investment Management LLC boosted its position in shares of Tandem Diabetes Care by 23.9% during the 3rd quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock worth $31,572,000 after acquiring an additional 293,250 shares in the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.